Instrument number PB 44 of 2009
Amendment special arrangements under subsection 100(1) of the National Health Act 1953
I, LINDA JACKSON, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.
Dated 1 May 2009
LINDA JACKSON
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program
1 Commencement
This instrument commences on 1 June 2009.
2 Amendment of PB 121 of 2008
Schedule 1 amends PB 121 of 2008.
Schedule 1 Amendments
[1] Schedule 2, item dealing with Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL
in the column headed “Brand” insert in alphabetical order:
Omegapharm Irinotecan
[2] Schedule 2, item dealing with Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL
in the column headed “Brand” insert in alphabetical order:
Omegapharm Irinotecan
[3] Schedule 2, item dealing with Vinorelbine in the form Solution for
I.V. infusion 10 mg (as tartrate) in 1 mL
omit from the column headed “Brand”:
Vinorelbine 10 Link
and substitute:
Vinorelbine Link
[4] Schedule 2, item dealing with Vinorelbine in the form Solution for
I.V. infusion 50 mg (as tartrate) in 5 mL
omit from the column headed “Brand”:
Vinorelbine 50 Link
and substitute:
Vinorelbine Link